Description
Introduction:
Liraglutide (NN2211) is a derivative of a human incretin (metabolic hormone), glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition.
Intended Use:
The KRIBIOLISA Liraglutide (Victoza/Saxenda)ELISA is used as for the quantitative determination of Liraglutide in human serum and plasma.
Principle:
The method employs a sandwich immunoassay for the determination of Liraglutide. The anti-Liraglutide Antibodies are coated on microtiter plate. Liraglutide standard and Liraglutide present in the samples will bind to coating antibody. Anti-GLP-1 antibody conjugated to HRP is then added which produces a soluble colored product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is directly proportional to the amount of bound Liraglutide present in the standards or samples.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!